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Abstract
Background
Human papillomavirus (HPV) types 16 and 18 cause invasive cervical cancer and most in-
vasive anal cancers (IACs). Overall, IAC rates are highest among men who have sex with
men (MSM), especially MSM with HIV infection. Testosterone is prescribed for men show-
ing hypogonadism and HIV-related wasting. While there are direct and indirect physiological
effects of testosterone in males, its role in anal HPV16/18 infections in men is unknown.
Methods
Free testosterone (FT) was measured in serum from 340 Multicenter AIDS Cohort Study
(MACS) participants who were tested for anal HPV16/18-DNA approximately 36 months
later. The effect of log10-transformed current FT level on anal HPV16/18 prevalence was
modeled using Poisson regression with robust error variance. Multivariate models con-
trolled for other HPV types, cumulative years of exogenous testosterone use, race, age, life-
time number of receptive anal intercourse partnerships, body mass index, tobacco
smoking, HIV-infection and CD4+ T-cell counts among HIV-infected, and blood draw timing.
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Results
Participants were, on average, 60 (+5.4) years of age, White (86%), and HIV-uninfected
(56%); Twenty-four percent tested positive for anal HPV16 and/or 18-DNA (HPV16 preva-
lence=17.1%, HPV18=9.1%). In adjusted analysis, each half-log10 increase of FT was as-
sociated with a 1.9-fold (95% Confidence Interval: 1.11, 3.24) higher HPV16/18 prevalence.
Additionally, other Group 1 high-risk HPVs were associated with a 1.56-fold (1.03, 2.37)
higher HPV16/18 prevalence. Traditional risk factors for HPV16/18 infection (age, tobacco
smoking; lifetime number of sexual partners, including the number of receptive anal inter-
course partnerships within 24 months preceding HPV testing) were poorly correlated with
one another and not statistically significantly associated with higher prevalence of HPV16/
18 infection in unadjusted and adjusted analyses.
Conclusions
Higher free testosterone was associated with increased HPV16/18 prevalence measured
approximately three years later, independent of sexual behavior and other potential con-
founders. The mechanisms underlying this association remain unclear and warrant
further study.
Introduction
Gay, bisexual and other men who have sex with men (MSM) are at high risk for both human
immunodeficiency virus (HIV) and human papillomavirus (HPV) infections [1–3]. Over 100
different HPVs are well characterized, of which 12–25 are sexually transmitted between part-
ners and are associated with high risk for cancers, including HPV types 16 (HPV16) and 18
(HPV18) [4, 5]. Experts classify HPV16 and 18 together with HPV31, 33, 35, 39, 45, 51, 52, 56,
58, and 59 as strongly carcinogenic (Group 1) high-risk HPVs (hrHPVs) because of associa-
tions with cervical cancers. HPV26, 30, 34, 53, 66, 67, 68, 69, 70, 73, 82, 85, and 97 show more
limited associations with human cancers and are classified as weakly carcinogenic (Group 2)
hrHPVs [4]. Nearly 72–90% of HPV-associated anal malignancies and over 70% of cervical
malignancies are causally related to HPV16 and 18 alone, making them of special interest
[6–9]. Other genital-tropic HPVs are classified as lower risk HPVs (lrHPVs) and are associated
with low-grade dysplasia including genital warts [4].
Sex hormones have been linked to HPV-related cervical cancers through the association be-
tween oral contraceptive (OC) use and parity in women [10]. For example, large human case-
control studies show OC use5 years increases risk for in situ and invasive cervical carcinoma
by approximately 3.4-fold [11–18]. Although few studies have explored sex hormone receptor
distribution in anal tissues, data suggest that androgen and estrogen receptors (AR, ER) are de-
tectable in stratified anal epithelium, with deeper strata showing greater abundance than more
superficial epithelium [19]. ERs and ARs are additionally detected in connective tissues under-
lying the anal epithelium [19]. Histological similarity suggest that the ectocervix and anus may
both support (HPV) carcinogenesis, but no data associate HPV infections and cancers with ex-
posures to androgens such as endogenous and exogenous testosterone, pharmacological equiv-
alents, and their downstream metabolites.
Available data suggest that frailty, hypogonadism, and wasting disease symptoms; as well as
age and obesity are associated with lower circulating serum testosterone levels [20–25]. In
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HIV-infected men, especially in those who develop AIDS-defining illnesses, testosterone levels
are lower than in HIV-uninfected men [20, 26]. Our goal was to evaluate the association be-
tween serum free testosterone (FT) and the prevalence of anal HPV16 and/or 18 (HPV16/18)
infections in a well-described cohort of MSM, and to identify possible risk factors for anal HPV
infection which may affect invasive anal cancer (IAC) risk.
Methods
Subjects
The Multicenter AIDS Cohort Study (MACS) protocol and its substudies, including the Anal
Health Study (AHS), were approved locally by institutional review boards at each of four U.S.
MACS study sites: (Baltimore) Johns Hopkins Bloomberg School of Public Health, (Chicago)
Northwestern University, (Los Angeles) UCLA, and (Pittsburgh) University of Pittsburgh.
Written informed consent for study procedures, specimen collection and testing were provided
by the sample of 340 men evaluated for this study.
Overall, the MACS has enrolled 6,972 HIV-infected and -uninfected MSM in its lifetime:
4,954 men were enrolled between 1984–1985, 668 men between 1987–1991, and 1,350 men be-
tween 2001–03 1,350 [27, 28]. By the year 2012, 2,291 MSM remained enrolled and active in
the MACS, of which 49% (1131/2291) were HIV-infected, and 61% (1389/2291) had been en-
rolled before 2001 [1]. Physical examination data, self- and interviewer-administered question-
naires for sociodemographic, sexual and other behavior characteristics, and laboratory
specimens, including blood serum and cells, are collected semi-annually.
Sample/Specimen Selection
These analyses reflect data from two separately conducted MACS sub-studies that evaluated
serum testosterone and anal HPVs among HIV-infected and -uninfected men. The testoster-
one study (parent study) evaluated the hypothesis that HIV-infection affected serum FT levels
using a nested case-control study design. Specifically, serum specimens for 542 HIV-infected
and -uninfected men45 years of age were retrospectively selected from the MACS repository
and tested for testosterone. Peripheral blood specimens collected from all men evaluated at
each study visit were separated into cells and serum at local sites and aliquots of varying vol-
umes were cryopreserved for long-term storage. Frozen serum specimens were shipped month-
ly on dry ice to the national MACS repository for all men completing a study visit. For these
analyses, testosterone-tested specimens for the parent study had been frozen and thawed once,
at most, prior to (testosterone) testing. Bolelli, et al. and others suggest testosterone analytes
are stable in frozen serum 10 or more years [29–31] and the specimens in this study had an av-
erage interval of 3.3 years (±2.2) between collection and testing.
Case and control specimens tested for the parent study were selected from repository sam-
ples and up to six serum specimens/subject were evaluated. Controls were matched to cases
based upon gender, race, enrollment period, study site, and specimen-collection (calendar)
time, and age (±5 years). HIV-infected men (cases) were selected if3 specimens were avail-
able, with1 samples collected3 years before beginning highly active antiretroviral therapy
(HAART), and2 samples collected within 10 years following HAART initiation. The avail-
ability and initiation of HAART varied among cases, and accordingly, temporally-matched test
specimens ranged widely. For men who later enrolled in the Anal Health Study, first specimens
tested for testosterone were collected between May, 1993 and February, 2006; similarly, the last
specimens tested in each subject’s specimen set were collected between June 1997 and January
2010. For each man, testosterone data for only one visit were included in the analysis (as de-
scribed in the “exposure of interest” section below).
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HPV data were collected as part of a second sub-study that began active enrollment of 1,504
men in March 2010. Anal swab specimens were collected using a standardized clinical protocol
and all active MACS men were eligible to participate [1, 32]. DNA extracted from swab speci-
mens were tested for HPV and samples were stored for 42 days on average before HPV testing
[1]; importantly, PreservCyt specimens may be stored at 2°- 30°C for up to 6 months before
HPV testing (Hologic, Inc., Bedford, MA) [33].
Thus, this study is best conceptualized as a voluntary follow-up study of 340 HIV-infected
and—uninfected men who were tested for FT as part of a passive, nested case-control analysis
of associations between serum FT, HIV-infection and HAART (S1 Fig., S1 Table). Specifically,
340 of 542 (63%) FT-tested men from the parent study were alive and elected to undergo anal
HPV testing. Non participants included 6% (33/542) of men who were lost to follow-up, 10%
(54/542) of whom died before the first HPV test visit, and 21% (115/542) of whom were eligible
but opted out of (HPV/cytology) testing. Together, sociodemographic, sexual and behavioral
data, and the FT measurement proximal to the HPV genotyping test visit were analyzed to test
the hypothesis that FT increased the probability of HPV16/18 infection.
The outcome of interest was HPV Type 16 or 18 DNA detected in anal swab specimens.
Each specimen was collected using a standard clinical protocol: A Dacron swab was inserted
approximately 2 inches beyond the anal verge, approximated to the wall and withdrawn, while
rotated, over ~30 seconds before being placed into 20 mL of preservative (PreservCyt, Cytyc
Corporation, Marlborough, MA) [1, 32]. A vortex mixer was used for several minutes to dis-
lodge the collected material from swabs within the preservative containers. DNA was extracted
from 250 μL of the cytology sample (Qiagen MinElute PCR Purification kit, Qiagen, Valencia,
CA), 50 μL was amplified (for HPV-DNA) using the PGMY09/11 primer system [34]. Dena-
tured PCR-products were hybridized to a probe array and were tested for 37 different HPVs
types, including HPV16 and-18, 18 other Group 1 and 2, strongly and weakly carcinogenic,
hrHPVs and 16 lrHPVs (Linear Array (HPV-LA) Roche Diagnostic Laboratories, Pleasanton,
California) [4, 35, 36]. To evaluate contamination, positive and negative controls are run with
each HPV-LA assay; data suggest the assay detects both single and multi-type infections more
sensitively than earlier technologies and target amplification assays [35, 36]. Less than 1% (3/
340) of first drawn cytology specimens were inadequate using HPV-LA; for those, findings
from the second visit were evaluated in these analyses.
FT, the exposure of interest, was derived from total testosterone measured in cryopreserved
serum using liquid chromatography-tandem mass spectrometry, and sex-hormone binding
globulin estimated from radioimmunoassay [26]. The Vermeulen equation was used to esti-
mate FT which closely approximates exact measures of FT obtained from equilibrium dialysis
methods [37]. For this assay, the lower threshold for normal specimens drawn in the morning
(AM) is 50 pg/mL [38, 39]. The FT measurement selected for these analyses was based on a fo-
cused preliminary assessment of the FT data. HAART initiation varied across the study group
and the series of FT measurements for each case and matched control straddled the first visit
where HAART use was reported by the index (matched) case in the parent study. Consequent-
ly, the first and last FT in the series of estimates from the parent study was collected, on aver-
age, 11.4 (+4.3) and 3.3 (+2.3) years before HPV testing, respectively. When considered
together, the average slope for each subject’s FT measurements over the observation period
was small, decreasing over time, and closely approximated for HIV-infected and -uninfected
men: i.e., for log10-transformed data, β = -0.003 (+0.06) and β = -0.007 (+0.03), respectively. FT
measured in serum was not statistically significantly associated with the time lapse between the
last FT measurement and the first HPV test visit (for log10-transformed data, β = 0.014, p =
0.175). Thus, the FT measurement closest to the HPV test visit was selected and evaluated for
these analyses.
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Other covariates
We evaluated demographic characteristics that were collected at semiannual visits, including
age, race (White non-Hispanic vs. others); other Group 1, Group 2 and low risk HPVs; tobacco
smoking, alcohol use, body mass index (kg/m2, BMI), HIV-infection characteristics at the
HPV test visit, and Hepatitis C virus (HCV) infection, known to be associated with FT [26].
Also, men who tested positive for1 of 9 other Group 1 strongly carcinogenic hrHPVs
(HPV31, 33, 35, 39, 45, 51, 52, 58, or 59), for any of 9 Group 2 weakly carcinogenic hrHPVs
(HPV26, 53, 66, 67, 68, 69, 70, 73, and 82), or for1 of 16 lrHPVs (HPV 6, 11, 40, 42, 54, 55,
61, 62, 64, 71, 72, 81, 83, 84, IS39, or CP6108) detected by the HPV-LA assay were compared to
men that tested negative, respectively [4, 35, 36]. The number of sexual partnerships and smok-
ing and alcohol use characteristics were evaluated over three periods: (1) lifetime exposure up
until the first ever MACS visit (MACS Visit 1), (2) cumulative exposure between each man’s
first MACS visit and the visit 24 months before HPV testing, and (3) the last 24 months before
HPV testing. Levels of alcohol and tobacco use showed no associations with HPV; thus, ever-
users of alcohol and tobacco during each period were compared to non-users. Associations be-
tween cumulative pack-years of tobacco use at visit 1, between visit 1 and the FT visit, and dur-
ing the last 24 months were poorly to modestly correlated (r = 0.40–0.65, p-values<0.001) and
poorly associated with HPV16/18 DNA detection in exploratory univariate and multivariate
analyses. However, ever having smoked prior to MACS visit 1, between the baseline MACS
visit and the FT visit, and during the last 24 months of observation were strongly correlated
(r = 0.64–0.97, p-values<0.001); for this reason, only smoking closest to the HPV test visit was
included in the final model. Those with BMI25 kg/m2 were compared to subjects with BMI
<25 kg/m2 men. For 32 men missing BMI measures at the testosterone visit, BMI measured at
the closest MACS visit was used. Men reporting>500, 201–500, and 51–200 lifetime sex part-
ners at MACS Visit 1 were compared to men who reported50 sex partners at MACS Visit 1.
Men who reported355, 133–354, and 63–132 partners, representing quartile cutoffs, between
MACS Visit 1 and the visit 24 months before HPV testing were compared to men who reported
<63 partners over the same interval. Men who reported4 and 1–3 receptive anal intercourse
(RAI) partners for the last 24 months prior to HPV testing were compared to those who re-
ported none. For 5 men missing RAI partnership data for1 study visits during the last 24
months of observation, the number reported at each of the last four visits with complete RAI
data before HPV testing were included. Lifetime cumulative duration of exogenous testoster-
one use in years was calculated for men who reported ever using exogenous testosterone. For
these analyses, exogenous testosterone products included Androderm (Actavis, Inc., Salt Lake
City, UT), AndroGel (AbbVie Inc., North Chicago, IL), Delatestryl (SAB-Pharma Inc., Bou-
cherville, QC, Canada), Striant (Mipharm S.p.A, Milan, Italy), Testoderm (Alza Corporation,
Mountain View, CA), and Virilon (Star Pharmaceuticals, Inc., North Miami Beach, FL). Data
for three MACS study sites were compared to data from the site with the largest population,
and men who enrolled early in the MACS, before 2001, were compared to those enrolled in
2001–2003 to control for sociodemographic differences. Time of phlebotomy was included in
the analysis to control for differences associated with diurnal variation in testosterone secre-
tion: before vs. after noon.
Statistical analysis
Participant characteristics were described overall, stratified by HPV16/18 infection and HIV-
status, using chi-squared and Fisher’s exact test. Risk factors for HPV16/18 positivity were as-
sessed in univariate and multivariate analysis using Poisson regression with robust error vari-
ance analyses, and prevalence ratios (PR) and 95% confidence intervals (95% CI) are reported
Free Testosterone and Anal HPV16/18 Infections
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[40]. The effect of testosterone level on HPV prevalence used half log10-transformed FT.
Cochran-Armitage tests for trend and Pearson correlation coefficients described associations
between continuous variables. Variables were eliminated from the full model using quasi-likeli-
hood under the independence model criterion statistics over four iterations.
Results
At the HPV study visit, on average, men were 60 (Standard Deviation (+): 5.4) years of age,
White (86%, 294/340), and more than half were HIV-uninfected (56%, 189/340; Table 1). The
FT measurement for the visit most closely preceding the HPV test visit varied widely (μ = 76.3
(+ 54.7) pg/mL), especially among HIV-infected men: 82.9 (+78.3) vs. 70.9 (+21.2), for HIV-
uninfected men (Table 2, S2 Fig.). Only 10% (34/340) of men reported ever using exogenous
testosterone and, among them, all were HIV-infected and 62% (21/34) showed BMI<25 kg/
m2. Smoking at the first MACS visit, at the FT and the HPV test visits were correlated with one
another, but not the number and character of sexual partnerships reported at these three visits
or with age or detection of HPV16/18 DNA. Median FT levels between HPV16/18-infected
and-uninfected men (75.2 vs. 65.5 pg/mL, p = 0.006) (Table 1), and HIV-infected and-
uninfected men (69.1 vs. 70.2 pg/mL, p = 0.04) (Table 2) differed. Although 21% (72/340) of
men showed clinically low FT (<50 pg/mL), HIV-infected men showed an almost 2-fold
higher odds of having FT below 50 pg/mL than HIV-uninfected men in the unadjusted analy-
sis: 28% (41/151) vs. 15% (30/189); OR = 2.04 (1.20, 3.46).
Nearly 24% (80/340) of participants tested HPV16/18-positive; of these, 17% (58/340) tested
positive for HPV16 and 9% (31/340) showed HPV18-DNA. Only 41% (33/80) tested positive
for HPV16 or-18 alone from among the 12 Group 1 hrHPVs [4]. Nearly 31% (105/340) of all
men tested positive for Group 1 hrHPVs other than HPV16/18, and men who tested positive
for Group 2 hrHPVs showed 1.6 times higher prevalence of HPV16/18-DNA than did men
who tested negative for Group 2 hrHPVs, 31% vs. 19% (p = 0.02). The prevalence of HPV16/18
was nearly as common among men testing positive for1 lrHPVs than not: 26% vs. 20%
(Table 1). HIV-infected men having500 CD4+ T-cells/mm3 had a higher prevalence of
HPV16/18 infection than HIV-infected men with>500 cells/mm3 and HIV-uninfected men:
37% (23/63) vs. 24% (21/88) vs. 19% (36/189), respectively (Cochran-Armitage Test for Trend,
p<0.01; Table 2). Men whose FT visit was more closely approximated to the HPV DNA test
visit were no more likely to test positive for HPV16/18 than those with longer intervals, mea-
sured in years (PR = 0.99 (0.92, 1.07)), and the time interval between FT and HPV test visits
was poorly correlated with FT (r2 = 0.04, p = 0.40). Additionally, the mean and variation of FT
levels for HPV16/18-infected men was greater than that for men that tested positive for other
Group 1 hrHPVs and those who tested negative for all Group 1 viruses (S3 Fig.).
The multivariate analysis showed that the prevalence of HPV16/18-DNA detected in anal
specimens increased 1.9-fold for each half log10 increase in FT (PR = 1.90 (95% CI: 1.11, 3.24)),
even after controlling for age, race, cumulative years of exogenous testosterone use, self-re-
ported lifetime number of sexual partnerships, BMI, tobacco smoking, HIV-infection and CD4
+ T-cell count, among the HIV-infected men, and the timing of blood draws (Table 3). Non-
Whites showed 2.3-fold higher prevalence of HPV16/18-DNA, though the estimate in the final
model was not statistically significant (p0.05) (Table 3). Prevalence of other Group 1
hrHPVs showed a 1.6-fold higher prevalence of HPV16/18 compared to those uninfected with
other Group 1 viruses; however, adjusted analyses showed no statistically significant associa-
tions between HPV16/18 infection and Group 2 hrHPVs or lrHPVs (i.e., PR = 1.26 (0.81, 1.96)
and 1.14 (0.74, 1.77)). Although not statistically significant, the adjusted model showed HIV-
infected men with500 CD4+ cells/mm3 had a 1.6-fold higher prevalence of HPV16/18 than
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Table 1. Characteristics of 340 Men Who Have Sex with Men Who Were Tested for Anal HPV DNA and Free Testosterone by HPV16/18 Positivity.
Characteristic HPV16 and/or 18a Positive N
(Column %)
HPV16 and HPV18 Negative N
(Column %)
Total N(Column
%)
pb
Age
45–49 3 (4) 6 (2) 9 (3) NS
50–59 38 (48) 124 (48) 162 (48)
60–69 34 (43) 121 (47) 155 (46)
70–79 4 (5) 9 (3) 13 (4)
80+ 1 (1) 0 (0) 1 (0)
Race
White Non-Hispanic 75 (94) 219 (84) 294 (86) 0.04
Non-White 5 (6) 41 (16) 46 (14)
HIV Infection
Negative 36 (45) 153 (59) 189 (56) 0.04
Positive 44 (55) 107 (41) 151 (44)
>500 CD4 T-cells/mm3 21 (48) 67 (63) 88 (58) NS
500 CD4 T-cells/mm3 23 (52) 40 (37) 63 (42)
Ever smoked tobacco within last 24 months before HPV testing
Yes 59 (74) 186 (72) 245 (72) NS
No 21 (26) 74 (28) 95 (28)
Ever drank alcohol within last 24 months before HPV testing
Yes 75 (94) 246 (95) 321 (94) NS
No 5 (6) 14 (5) 19 (6)
HPV16/18
Positive - - 80 (24) -
Negative - - 260 (76) -
Group 1 hrHPVs
HPV16, 18 only - - 33 (9) NS
HPV16, 18, & other - - 47 (14)
Other Group 1 hrHPVs Only (No 16/
18)
- - 105 (31)
Negative - - 155 (46)
Group 2 hrHPVs
Positive 37 (46) 82 (32) 119 (21) 0.02
Negative 43 (154) 178 (68) 221 (79)
lrHPVs
Positive 54 (68) 155 (60) 209 (61) NS
Negative 26 (32) 105 (40) 131 (39)
Use of exogenous testosterone
Yes 12 (15) 22 (8) 34 (10) NS
No 68 (85) 238 (92) 306 (90)
Hepatitis C Virusc
Positive 4 (5) 14 (5) 18 (5) NS
Negative 76 (95) 246 (95) 322 (95)
Study Center
1 Baltimore 22 (28) 64 (25) 86 (24) NS
2 Chicago 11 (14) 54 (21) 65 (19)
3 Pittsburgh 13 (16) 39 (15) 52 (15)
4 Los Angeles 34 (43) 103 (40) 137 (40)
(Continued)
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did HIV-uninfected men; and, the HPV16/18 prevalence was 1.2-times higher for HIV-
infected men showing>500 CD4+ cells/mm3. The fully-adjusted analysis suggested that the
number of receptive anal intercourse partnerships within the 24 months preceding the HPV
test visit did not statistically significantly affect the prevalence of HPV16/18 DNA detected in
anal swab specimens (e.g., for 1–3 and4 partners: PR = 1.42 (0.89, 2.28) and 1.23 (0.76, 1.98),
respectively), nor did partnerships reported earlier in the study period (Table 3).
Discussion
HPV16/18 infections are extremely relevant in clinical practices where HIV-infected and
-uninfected MSM are treated. Finding that higher serum FT, measured approximately 3 years
before testing, increased risk for detecting HPV16/18-DNA in anal swab specimens suggests a
causal temporal relationship. These findings support our hypothesis that testosterone, a sex ste-
roid hormone, will affect productive HPV infections. In this study group, only HIV-infected
men reported exogenous testosterone use but also showed statistically significantly lower FT
Table 1. (Continued)
Characteristic HPV16 and/or 18a Positive N
(Column %)
HPV16 and HPV18 Negative N
(Column %)
Total N(Column
%)
pb
Enrollment
2001–03 10 (13) 27 (10) 37 (11) NS
Pre-2001 70 (88) 233 (90) 303 (89)
Number of male sex partnerships reported at baseline (MACS Visit 1)
Greater than 500 18 (23) 63 (24) 81 (24) NS
201–500 21 (26) 50 (19) 71 (21)
51–200 21 (26) 81 (31) 102 (30)
50 or fewer 20 (25) 66 (25) 86 (25)
Number of male sex partners reported between MACS Visit 1 to 24 months prior to HPV testing
355+ 19 (24) 66 (25) 85 (25) NS
133–354 16 (20) 68 (26) 84 (25)
63–132 25 (31) 59 (23) 84 (25)
Fewer than 63 20 (25) 67 (26) 87 (26)
Number of receptive anal intercourse partners within 24 months before HPV testing
4+ 26 (33) 69 (27) 95 (28) NS
1–3 21 (26) 55 (21) 76 (22)
0 33 (41) 136 (52) 169 (50)
BMI
25 kg/m2 37 (46) 152 (58) 189 (56) NS
<25 kg/m2 43 (54) 108 (42) 151 (44)
Free Testosterone (FT) level
Above Median (70.1 pg/mL) 52 (65) 118 (45) 170 (50) 0.003
Median and Below 28 (35) 142 (55) 170 (50)
Median (IQR) Median (IQR) Median (IQR)
FT 75.2 (63.0, 89.4) 65.5 (51.2, 83.3) 70.1 (53.6, 84.7) -
Slope of log10FT Change/year 0.000 (-0.01, 0.02) -0.005 (-0.02, 0.01) -0.003 (-0.01,
0.01)
NS
a Positive for either HPV16 or HPV18 or both
b Fisher’s Exact (2-sided) p-values: comparisons between groups in total population; NS: p0.05
c HCV antibody positivity
doi:10.1371/journal.pone.0119447.t001
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levels, on average. These phenomenon are similarly reported by other investigators [20, 26],
suggesting that in the absence of treatment, mean levels may have been even lower in HIV-
infected than -uninfected men. Nonetheless, finding that higher FT increases risk for HPV16/
18 infections some three years after its measurement may be important to carcinogenesis.
HPV16/18 and 10 other hrHPVs are necessary but alone insufficient causes of human cancer
Table 2. Socio-Demographic, Examination, Sexual and Other Behavioral Characteristics of 151 HIV-Infected and 189 HIV-Uninfected Men Who
Have Sex with Men Who Were Tested for Anal HPV16/18 DNA and Free Testosterone at Separate Study Visits.
HIV-infected HIV-uninfected Total
(N = 151) (N = 189) (N = 340)
Characteristics n (%) n (%) n (%)
HPV16/18 positive 44 (29) 36 (19) 80 (24)
Use of exogenous testosterone 34 (22.5) 0 (0) 34 (10.0)
Time of testosterone measurement
AM 44 (29) 36 (19) 80 (24)
PM 107 (71) 153 (81) 260 (76)
Race
White Non-Hispanic 129 (85.4) 165 (87.3) 294 (87)
Non-White 22 (14.6) 24 (12.7) 46 (13)
Ever smoked tobacco within last 24 months before HPV testing
Yes 116 (76.8) 129 (68.3) 245 (72.1)
No 35 (23.2) 60 (31.8) 95 (27.9)
BMI
25kg/m2 69 (45.7) 120 (63.5) 189 (55.6)
<25kg/m2 82 (54.3) 69 (36.5) 151 (44.4)
Mean
(SD)
Median (IQR) Mean
(SD)
Median (IQR) Mean (SD) Median (IQR)
FT Level (pg/mL)a 82.9
(78.3)
69.1 (48.0,
84.0)
70.9
(21.2)
70.2 (56.7,
83.5)
76.3 (54.7)
(54.7)
70.1 (53.6,
84.7)
Age (years) 60.4 (5.2) 60.5 (57.6,
63.3)
59.5 (5.5) 59.3 (55.8,
63.1)
59.9 (5.4) 59.9 (56.4,
63.2)
Number of male sexual partners reported
At MACS Visit 1 432
(492.1)
300 (75, 600) 294
(351.4)
101 (40, 450) 356 (424.7) 200 (50, 500)
Between MACS Visit 1–24 months before the HPV test
visit
338
(710.6)
126 (59, 356) 297
(406.5)
142 (62, 351) 315 (561.7) 132 (62, 354)
Number of receptive anal intercourse sexual partnerships reported
Within 24 months before HPV testing 5.4 (12.6) 1 (0, 5.0) 3.6 (8.5) 0 (0, 4.0) 4.4 (10.5) 1 (0, 4.0)
CD4 T-cell count (T-cells/mm3) 589
(231.7)
544 (451, 708) 914
(268.9)
888 (722,
1103)
769 (300.0) 734 (522, 969)
Time between last FT specimen of (FT) test series
and HPV testing (years)b
2.8 (1.8) 2.0 (1.0, 4.0) 3.8 (2.6) 3.0 (2.0, 5.0) 3.3 (2.3) 3.0 (2.0, 5.0)
Time between first FT specimen of (FT) test series
and HPV testing (years)
11.1 (4.3) 13.0 (7.0, 15.0) 11.7 (4.3) 14.0 (8.0, 15.0) 11.4 (4.3) 13 (8.0, 15.0)
Slope (change log10FT/year between first to last FT
visit)
-0.003
(0.06)
-0.002 (-0.02.
0.01)
-0.007
(0.03)
-0.003 (-0.01,
0.01)
-0.006 (0.45) -0.003 (-0.01,
0.01)
a Wilcoxon two-sample test (exact test): comparing FT medians for HIV-infected vs. uninfected, two-sided test: Z = -.8128 p = 0.42
b Wilcoxon two-sample test (exact test): comparing time between index FT and HPV tests, for HIV-infected vs. uninfected, two-sided test: Z = -3.7069, p =
0.0002
doi:10.1371/journal.pone.0119447.t002
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Table 3. Univariate and Four Iterations of Multivariate Evaluation of Risk Factors for Anal HPV16/18 DNA Positivity for 340 Men Who Have Sex
with Men.a
Unadjusted Multivariate Adjusted
Model 1 Model 2 Model 3 Model 4
N HPV16/18Positive (% of
total)
Prevalence Ratio (PR) (95%
CI)
PRb (95% CI) PRc (95% CI) PRd (95% CI) PRe (95% CI)
Half Log10
Increase
Testosterone
(centered
around the
mean)
340 80 (24) 1.96 (1.38, 2.79) 1.80 (1.05,
3.11)
1.82 (1.03,
3.21)
1.87 (1.06,
3.27)
1.90 (1.11,
3.24)
Cumulative
Years of
(Exogenous)
Testosterone
Use (per
year)
340 80 (24) 1.08 (0.98, 1.20) 0.93 (0.82,
1.05)
0.94 (0.82,
1.07)
0.94 (0.82,
1.07)
0.92 (0.81,
1.05)
Other Group 1 hrHPVs (HPV 31, 33, 35, 39, 45, 51, 52, 58, or 59)
Yes 152 47 (31) 1.76 (1.19, 2.60) 1.71 (1.11,
2.62)
1.63 (1.06,
2.50)
1.62 (1.06,
2.47)
1.56 (1.03,
2.37)
No 188 33 (18) 1 1 1 1 1
Group2 hrHPVs (HPV 26, 53, 66, 67, 68, 69, 70, 73, or 82)
Yes 119 37 (31) 1.60 (1.09 2.33) 1.21 (0.78,
1.88)
1.26 (0.81,
1.95)
1.25 (0.81,
1.93)
1.26 (0.81,
1.96)
No 221 43 (19) 1 1
Low Risk HPVs (HPV 6, 11, 40, 42, 54, 55, 61, 62, 64, 71, 72, 81, 83, 84, IS39, or CP6108)
Yes 209 54 (26) 1.30 (0.86, 1.97) 1.28 (0.79,
2.07)
1.25 (0.78,
1.99)
1.22 (0.77,
1.94)
1.14 (0.74,
1.77)
No 131 26 (19) 1 1
Age
340 80 (24) 1.00 (0.92, 1.08) 1.00 (0.96,
1.05)
1.00 (0.94,
1.22)
1.00 (0.93,
1.21)
0.99 (0.95,
1.23)
Race
White 294 75 (26) 2.35 (1.00, 5.49) 2.57 (1.14,
5.81)
2.66 (1.18,
6.00)
2.77 (1.19,
6.44)
2.27 (0.97,
5.30)
Non-White 46 5 (11) 1 1 1 1 1
HIV Infection
HIV-infected (CD4 T-cells/mm3)
>500 88 21 (24) 1.25 (0.78, 2.01) 1.22 (0.73,
2.03)
1.15 (0.69,
1.90)
1.16 (0.70,
1.90)
1.23 (0.76,
2.00)
500 63 23 (37) 1.92 (1.24, 2.97) 1.73 (1.01,
2.04)
1.62 (0.97,
2.71)
1.58 (0.95,
2.64)
1.61 (0.96,
2.70)
Uninfected 189 36 (19) 1 1 1 1 1
Time of Testosterone Measurement
AM 255 61 (24) 1.07 (0.68, 1.68) 1.13 (0.66,
1.92)
1.10 (0.66,
1.83)
1.09 (0.65,
1.83)
0.99 (0.62,
1.57)
PM 85 19 (22) 1 1 1 1 1
Number of Lifetime Male Intercourse Partners at MACS Visit 1
500+ 81 18 (22) 0.96 (0.55, 1.67) 0.94 (0.50,
1.76)
0.90 (0.48,
1.66)
0.89 (0.48,
1.67)
0.92 (0.50,
1.68)
201–500 71 21 (26) 1.27 (0.75, 2.15) 1.17 (0.66,
2.07)
1.12 (0.64,
1.96)
1.09 (0.62,
1.93)
1.14 (0.66,
1.98)
(Continued)
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[4], and persistent HPV16/18-DNA has been detected in both anal high-grade squamous
intraepithelial lesions (HSIL) and IACs using worldwide samples. For example, 75–81% of
HSIL and IAC lesions test positive for HPV16 DNA alone [41]. However, some might propose
associations between FT and HPV16/18 infections are irrelevant because some data suggest
persistent anal infections are uncommon and clearance is relatively rapid among high-risk
MSM [42]. HPV-clearance may be more difficult to measure because small, persistent focal in-
fections with low-copy number may be undetectable, even using sensitive molecular assays [5].
Nonetheless, clearance of HPV is less frequently observed for HPV16 [5, 43] than among other
hrHPVs: e.g., 12.2 vs. 19.5–57.2/1000 person months in one large study [42, 44].
Most men in this study showed higher serum FT values when compared to the lower thresh-
old for clinically normal values [38, 39]. Sex hormones have long been associated with HPV-
Table 3. (Continued)
Unadjusted Multivariate Adjusted
Model 1 Model 2 Model 3 Model 4
N HPV16/18Positive (% of
total)
Prevalence Ratio (PR) (95%
CI)
PRb (95% CI) PRc (95% CI) PRd (95% CI) PRe (95% CI)
51–200 102 21 (21) 0.89 (0.52, 1.52) 0.77 (0.45,
1.30)
0.80 (0.47,
1.35)
0.79 (0.46,
1.34)
0.81 (0.48,
1.36)
50 86 20 (23) 1 1 1 1 1
Sum of Number of Male Intercourse Partners Since Last Visit Reported from MACS Visit 1 to 24 Months Prior to HPV Testing
355+ 85 19 (22) 0.97 (0.56, 1.69) 0.68 (0.34,
1.38)
0.74 (0.38,
1.44)
0.76 (0.39,
1.47)
0.66 (0.34,
1.26)
133–354 84 16 (19) 0.83 (0.46, 1.49) 0.61 (0.32,
1.14)
0.64 (0.34,
1.18)
0.66 (0.36,
1.22)
0.62 (0.34,
1.12)
63–132 84 25 (30) 1.29 (0.78, 2.15) 1.12 (0.66,
1.89)
1.15 (0.68,
1.95)
1.19 (0.70,
2.01)
1.11 (0.66,
1.87)
62 87 20 (23) 1 1 1 1 1
Number of Receptive Anal Intercourse Partners in the 24 Months Prior to HPV testing
4 95 26 (27) 1.40 (0.90, 2.19) 1.08 (0.63,
1.85)
1.13 (0.67,
1.91)
1.13 (0.67,
1.91)
1.23 (0.76,
1.98)
1–3 76 21 (28) 1.42 (0.88, 2.28) 1.24 (0.74,
2.05)
1.34 (0.81,
2.20)
1.32 (0.81,
2.15)
1.42 (0.89, 2.
28)
0 169 33 (20) 1 1 1 1 1
BMI
25kg/
m2
189 37 (20) 0.69 (0.47, 1.01) 0.88 (0.57,
1.34)
0.86 (0.57,
1.31)
0.87 (0.57,
1.31)
0.87 (0.57,
1.32)
<25kg/
m2
151 43 (28) 1 1 1 1 1
Ever smoked tobacco within last 24 months before HPV testing
Yes 245 59 (24) 1.09 (0.70, 1.69) 0.79 (0.10,
6.25)
0.99 (0.63,
1.54)
0.99 (0.63,
1.55)
1.01 (0.65,
1.57)
No 95 21 (22) 1 1 1 1 1
a Statistically significant associations appear in bold type-face, p<0.05
b Additionally controlled for Hepatitis C virus (HCV), smoking and alcohol use prior to baseline and testosterone testing visit, cumulative pack years prior
to baseline, testosterone visit, and HPV testing visit, study site, and time cohort, QIC = 508.5534.
c Additionally controlled for Hepatitis C virus (HCV), alcohol use prior to HPV testing visit, study site, and time cohort, QIC = 501.2063.
d Additionally controlled for study site, and time cohort, QIC = 506.7745.
e QIC = 491.2723
doi:10.1371/journal.pone.0119447.t003
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malignancies in women [5]. For example, in vitro studies show 17β-estradiol stimulates the
promoter and increases HPV oncogene expression in well-described cancer cell lines [45]. Oth-
ers report estrogen and androgen receptors alike are detectable in anal squamous epithelium,
making a biological association between focal anal HPV16/18 infections and FT more plausible
[19]. However, we find no prior studies have evaluated the associations between FT and either
HPV16/18 infections or IAC incidence. However, these data suggest that the prevalence of anal
HPV16/18 infection in men nearly doubles with each half log10 increase of serum FT, even
after controlling for the effects of other covariates, including age and exogenous
testosterone use.
Like others, while some early analyses herein showed HIV-infection and lower CD4+ T-cell
counts showed higher risk of HPV16/18 infection, the association was not statistically signifi-
cant in the final model [46]. Nonetheless, some investigators report a positive association be-
tween CD4+ T-cell counts and infection risk at levels lower than the 500 CD4+ T-cells/mm3
cut-point reported here [46, 47]. Together, the direction and magnitude of our point estimates
suggest that we may have lacked the power to detect a positive association between HIV and
HPV16/18 infections as well as higher risk for men with lower CD4+ cell counts over men with
higher values. Tobacco smoking [46, 48, 49], the number of sexual partners [32, 47, 50], and
age [47, 50] have been positively associated with hrHPV infections and IACs. For example, cur-
rent smokers vs. non- or never-smokers may show 1.23 to 2.59-fold higher risk for hrHPV in-
fections and IACs [46, 48, 49]. Reports for some show that men with>100 lifetime male sex
partners have a 30–40% higher risk for hrHPV seropositivity than men reporting fewer part-
ners [47]; however, others report risk for anal hrHPVs is only elevated among HIV-uninfected
MSM reporting>100 lifetime sexual partners, with no measurable effect among HIV-infected
MSM [50]. Comparatively, when data described herein are stratified, we found a similar pro-
portional distribution of men with<100, 100–500, and>500 lifetime sexual partnerships
(data not shown). However, exploratory analyses still showed no statistically significant associ-
ations between the number of lifetime sexual partners and a more narrowly defined hrHPV
subset, HPV16/18-DNA, either overall or among HIV-uninfected men alone. While these rela-
tionships may indicate associations between FT may more strongly influence prevalence of
HPV16/18, they also suggest MACS men may have been more highly exposed to hrHPVs over
their lifetimes than other MSM groups reported in the literature. Some differences may be re-
lated to differences in methodological approaches. For example, some published comparisons
showing associations evaluated HPV16/18 outcomes using serology [47, 51]; however, some
also reported associations between HPV16/18 and traditional risk factors such as tobacco
smoking and sexual partnerships, when employing PCR-based (HPV) DNA assays similar to
those reported herein [32, 46, 48–50].
HIV-infection increases the risk of hypogonadism and wasting, increasing the chances of
prescribed testosterone replacement therapy [20, 23]. While as few as 15–16% of HIV-infected
and -uninfected males show measurably low serum testosterone, low serum values are positive-
ly associated with higher risk of muscle wasting [20, 39, 52, 53]. Testosterone use in the absence
of wasting or hypogonadism may not be recommended but would be relevant to our findings.
For example, HIV-treatment guidelines suggest many MSMmay be eligible for screening and
treatment using testosterone: those with lower libido or erectile dysfunction, reduced bone
mass or non-traumatic fractures; hot flashes, night-sweats, or fatigue and depression [54].
However, despite the relatively narrow screening and treatment recommendation, regardless of
HIV-infection [39, 54], recent domestic and worldwide estimates suggest therapeutic use is in-
creasing dramatically. For example, a 12-fold increase in testosterone prescription occurred be-
tween 2000 and 2011, with rates increasing>9-fold, from 10.3 to 98.5 monthly doses/1000
U.S. males [23, 55]. Together, these data suggest that testosterone use, therapeutically indicated
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or not, may be increasing and that older MSM who use testosterone may be at higher risk for
HPV16/18 infections that are often linked to IACs [1, 41].
These analyses may be limited. For example, the sample size may be insufficient to detect as-
sociations between smoking, age, and sexual risk factors commonly associated with hrHPV in-
fections in adults. Men evaluated for testosterone were unaware of their inclusion in the
original investigation. Selection bias may limit our findings; for example, specimens for HIV-
infected men selected from the repository for FT testing may not reflect a random sample of
HIV-positive participants from the baseline cohort to which controls were matched. Further
HIV-infected men surviving into the HAART era may not reflect the on-average experience or
biological characteristics of the original cohort. Exogenous testosterone use, dose, route and
source are not fully captured in these data, as use is recorded dichotomously at each semi-
annual visit. Dichotomizing the phlebotomy time (before vs. after noon) may not adequately
control for fluctuations in testosterone associated with physiologic diurnal variation. Also,
other sex hormones were not measured; for example, we cannot evaluate the effect that testos-
terone conversion to estradiol, through the aromatase pathway, might have on HPV16/18
prevalence in these men [56]. Nonetheless, when polychotomous variables (e.g., number of sex
partners) are misclassified or when misclassification varies for one variable across levels of co-
variates, the direction and magnitude of confounding cannot be estimated [57]. Additionally,
the HPV-LA assay cannot distinguish between HPV52 and HPV33, 35, and 38, suggesting
some conditions may be ambiguous; however, for these analyses, HPV33, 35, 38 and 52 are
evaluated as a single categorical variable with 6 other Group 1 viruses [58]. Last, only 9 of 13
Group 2 HPVs are characterized by the HPV-LA and while the assay still reports findings for
HPV-CP6108, the virus is also referred to as HPV89, a lrHPV [59].
Ideal use of testosterone-replacement therapy returns testosterone levels to age-appropriate
norms, relieves symptoms, and prevents disease for deficient men without harmful side-effects
[39, 60, 61]. Clinically, the results from these analyses suggest some risk may be associated with
therapeutic and off-label use of testosterone in MSM who are at high risk for exposure to
HPV16/18 [1, 32, 62]. A cautious approach to testosterone use in HIV-infected MSMmay be
indicated. Understanding associations between FT and persistent anal HPV16/18 infections
will improve scientific understanding and inform therapeutic strategies.
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